Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 6/20 | 1.00 |
| ▸ | IARS1 | P41252 | 2/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | SARS1 | P49591 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069778 | 0.88 | MARS1 (0.80) | MARS1IARS1SARS1 | |
| SCHEMBL4308351 | 0.83 | MARS1 (1.00) | MARS1IARS1SARS1 | |
| SCHEMBL21067350 | 0.83 | MARS1 (1.00) | MARS1IARS1SARS1 | |
| SCHEMBL178820 | 0.83 | MARS1 (1.00) | MARS1IARS1SARS1 | |
| SCHEMBL178826 | 0.83 | MARS1 (1.00) | MARS1IARS1SARS1 | |
| SCHEMBL13773213 | 0.79 | MARS1 (0.82) | MARS1IARS1SARS1 | |
| SCHEMBL13773214 | 0.79 | MARS1 (0.82) | MARS1IARS1SARS1 | |
| SCHEMBL13773212 | 0.79 | MARS1 (0.82) | MARS1IARS1SARS1 | |
| SCHEMBL5362281 | 0.79 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5362267 | 0.79 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885IARS1 46/4885ADORA2A 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.